Late-stage studies of AstraZeneca’s COVID-19 vaccine candidate are on temporary hold while the company investigates whether a recipient’s “potentially unexplained” illness is a side effect of the shot. In a statement issued Tuesday evening, the company said its “standard review process triggered a pause to vaccination to allow review of safety data.” AstraZeneca didn’t reveal any information about the possible side effect except to call it “a potentially unexplained illness.” … An AstraZeneca spokesperson confirmed the pause in vaccinations covers studies in the U.S. and other countries.